IBDEI15B ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19491,0)
 ;;=L56.0^^84^918^139
 ;;^UTILITY(U,$J,358.3,19491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19491,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,19491,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,19491,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,19492,0)
 ;;=L56.1^^84^918^138
 ;;^UTILITY(U,$J,358.3,19492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19492,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,19492,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,19492,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,19493,0)
 ;;=L56.2^^84^918^236
 ;;^UTILITY(U,$J,358.3,19493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19493,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,19493,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,19493,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,19494,0)
 ;;=L56.3^^84^918^268
 ;;^UTILITY(U,$J,358.3,19494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19494,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,19494,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,19494,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,19495,0)
 ;;=L57.0^^84^918^12
 ;;^UTILITY(U,$J,358.3,19495,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19495,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,19495,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,19495,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,19496,0)
 ;;=L60.0^^84^918^161
 ;;^UTILITY(U,$J,358.3,19496,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19496,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,19496,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,19496,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,19497,0)
 ;;=L60.1^^84^918^234
 ;;^UTILITY(U,$J,358.3,19497,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19497,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,19497,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,19497,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,19498,0)
 ;;=L60.2^^84^918^233
 ;;^UTILITY(U,$J,358.3,19498,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19498,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,19498,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,19498,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,19499,0)
 ;;=L60.3^^84^918^170
 ;;^UTILITY(U,$J,358.3,19499,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19499,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,19499,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,19499,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,19500,0)
 ;;=L60.4^^84^918^88
 ;;^UTILITY(U,$J,358.3,19500,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19500,1,3,0)
 ;;=3^Beau's Lines
 ;;^UTILITY(U,$J,358.3,19500,1,4,0)
 ;;=4^L60.4
 ;;^UTILITY(U,$J,358.3,19500,2)
 ;;=^5009237
 ;;^UTILITY(U,$J,358.3,19501,0)
 ;;=L60.5^^84^918^290
 ;;^UTILITY(U,$J,358.3,19501,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19501,1,3,0)
 ;;=3^Yellow Nail Syndrome
 ;;^UTILITY(U,$J,358.3,19501,1,4,0)
 ;;=4^L60.5
 ;;^UTILITY(U,$J,358.3,19501,2)
 ;;=^5009238
 ;;^UTILITY(U,$J,358.3,19502,0)
 ;;=L60.8^^84^918^168
 ;;^UTILITY(U,$J,358.3,19502,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19502,1,3,0)
 ;;=3^Nail Disorders NEC
 ;;^UTILITY(U,$J,358.3,19502,1,4,0)
 ;;=4^L60.8
 ;;^UTILITY(U,$J,358.3,19502,2)
 ;;=^5009239
 ;;^UTILITY(U,$J,358.3,19503,0)
 ;;=L62.^^84^918^169
 ;;^UTILITY(U,$J,358.3,19503,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19503,1,3,0)
 ;;=3^Nail Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,19503,1,4,0)
 ;;=4^L62.
 ;;^UTILITY(U,$J,358.3,19503,2)
 ;;=^5009241
 ;;^UTILITY(U,$J,358.3,19504,0)
 ;;=L64.9^^84^918^33
 ;;^UTILITY(U,$J,358.3,19504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19504,1,3,0)
 ;;=3^Androgenic Alopecia,Unspec
 ;;^UTILITY(U,$J,358.3,19504,1,4,0)
 ;;=4^L64.9
